Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis

References

• From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2017. Available from: http://www.ginasthma.org/
   Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:1–15.
   Web of Science ®Google Scholar
• Porsbjerg C, Ulrik C, Skjold T, et al. Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults. Eur Clin Respir J. 2018;5:1440868.
   PubMed Web of Science ®Google Scholar
• von Bülow A, Kriegbaum M, Backer V, et al. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract. 2014;2:759–767.
   PubMed Web of Science ®Google Scholar
• Luskin AT, Chipps BE, Rasouliyan L, et al. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract. 2014;2:544.e2-552.e2.
   Web of Science ®Google Scholar
• Braman SS. The global burden of asthma. Chest. 2006;130:4S12S.
   Web of Science ®Google Scholar
• Varsano S, Segev D, Shitrit D. Severe and non-severe asthma in the community: a large electronic database analysis. Respir Med. 2017;123:131–139.
   PubMed Web of Science ®Google Scholar
• Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. The Lancet. 2008;372:1107–1119.
   PubMed Web of Science ®Google Scholar
• Amini-Vaughan ZJ, Martinez-Moczygemba M, Huston DP. Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer. Curr Allergy Asthma Rep. 2012;12:402–412.
   Web of Science ®Google Scholar
• Nixon J, Newbold P, Mustelin T, et al. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacol Ther. 2017;169:57–77.
   PubMed Web of Science ®Google Scholar
• Brown P, Brunnhuber K, Chalkidou K, et al. How to formulate research recommendations. BMJ. 2006;333:804–806.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535–b2535.
   PubMed Web of Science ®Google Scholar
• Danish Medicines Council. Process and methods guide – how the Danish medicines council assesses several medicines within the same therapeutic area [Internet]. 2017 [cited 2018 Mar 16]; Available from: http://www.medicinraadet.dk/media/5204/process-and-methods-guide-how-the-danish-medicines-council-assesses-several-medicines-within-the-same-therapeutic-area.pdf
   Google Scholar
• Danish Medicines Council. Protokol for medicinrådets kliniske vurdering af biologiske lægemidler til svær astma [Internet]. 2017 [cited 2018 Mar 16]; Available from: http://www.medicinraadet.dk/media/4976/protokol-for-klinisk-vurdering-af-biologiske-laegemidler-til-svaer-astma_-vers10.pdf
   Google Scholar
• Danish Medicines Council. Medicinrådets behandlingsvejledning for biologiske lægemidler til svær astma [Internet]. 2018 [cited 2018 Mar 16]; Available from: http://www.medicinraadet.dk/media/7407/behandlingsvejledning-svaer-astma-10.pdf
   Google Scholar
• European Medicines Agency. Summary of products characteristics – nucala [Internet]. 2015 [cited 2018 Mar 16]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003860/WC500198037.pdf
   Google Scholar
• Danish Society of Respiratory Medicine. Severe Asthma [Internet]. Dan. Lungemedicinsk Selsk.1970 [cited 2018 Mar 19]; Available from: https://www.lungemedicin.dk/
   Google Scholar
• Reddel HK, Taylor DR, Bateman ED, et al. An official American thoracic society/european respiratory society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59–99.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gotzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928–d5928.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683–691.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–1207.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390–400.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet Lond Engl. 2012;380:651–659.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al., SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–1197.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150:789–798.
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1125–1132.
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799–810.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355–366.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4:549–556.
   PubMed Web of Science ®Google Scholar
• Ortega H, Chupp G, Bardin P, et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. Eur Respir J. 2014;44:239–241.
   PubMed Web of Science ®Google Scholar
• Magnan A, Bourdin A, Prazma CM, et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy. 2016;71:1335–1344.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Germinaro M, Weiss S, et al. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther. 2017;43:39–45.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Canvin J, Weiss S, et al. Stratification of eosinophilic asthma patients treated with reslizumab and GINA step 4 or 5 therapy. ERJOpen Res. 2017 Aug 17;3(3). pii: 00004–2017. doi: 10.1183/23120541.00004-2017. eCollection 2017 Jul.
   Google Scholar
• Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834.
   PubMed Web of Science ®Google Scholar
• Rice JB, White AG, Scarpati LM, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39:2216–2229.
   PubMed Web of Science ®Google Scholar
• Gibson PG, McDonald VM. Management of severe asthma: targeting the airways, comorbidities and risk factors. Intern Med J. 2017;47:623–631.
   PubMed Web of Science ®Google Scholar
• von Bülow A, Backer V, Bodtger U, et al. The level of diagnostic assessment in severe asthma: a nationwide real-life study. Respir Med. 2017;124:21–29.
   Web of Science ®Google Scholar
• Gibeon D, Heaney LG, Brightling CE, et al. British thoracic society difficult asthma network. Dedicated severe asthma services improve health-care use and quality of life. Chest. 2015;148:870–876.
   PubMed Web of Science ®Google Scholar
• National Health Services England. Specialised respiratory services (adult) – severe asthma [Internet]. UK: National Health Service; 2017 cited 2017 Jan 1 Available from: https://www.england.nhs.uk/publication/specialised-respiratory-services-adult-severe-asthma/
   Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176:1062–1071.
   PubMed Web of Science ®Google Scholar